Coherus Oncology, Inc. (CHRS)
1.08
+0.03
(+2.86%)
USD |
NASDAQ |
Oct 15, 10:50
Coherus Oncology Total Long Term Debt (Quarterly) : 52.23M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 52.23M |
| March 31, 2026 | 52.47M |
| December 31, 2025 | 52.54M |
| September 30, 2025 | 52.53M |
| June 30, 2025 | 52.37M |
| March 31, 2025 | 297.78M |
| December 31, 2024 | 296.96M |
| September 30, 2024 | 297.85M |
| June 30, 2024 | 296.91M |
| March 31, 2024 | 479.35M |
| December 31, 2023 | 479.42M |
| September 30, 2023 | 478.68M |
| June 30, 2023 | 479.26M |
| March 31, 2023 | 479.86M |
| December 31, 2022 | 477.30M |
| September 30, 2022 | 480.72M |
| June 30, 2022 | 431.76M |
| March 31, 2022 | 430.34M |
| December 31, 2021 | 416.27M |
| September 30, 2021 | 418.77M |
| June 30, 2021 | 414.53M |
| March 31, 2021 | 414.90M |
| December 31, 2020 | 415.41M |
| September 30, 2020 | 414.30M |
| June 30, 2020 | 413.85M |
| Date | Value |
|---|---|
| March 31, 2020 | 190.24M |
| December 31, 2019 | 188.64M |
| September 30, 2019 | 188.60M |
| June 30, 2019 | 183.15M |
| March 31, 2019 | 183.16M |
| December 31, 2018 | 103.09M |
| September 30, 2018 | 102.71M |
| June 30, 2018 | 102.33M |
| March 31, 2018 | 101.97M |
| December 31, 2017 | 101.61M |
| September 30, 2017 | 101.26M |
| June 30, 2017 | 100.92M |
| March 31, 2017 | 100.58M |
| December 31, 2016 | 100.26M |
| September 30, 2016 | 99.94M |
| June 30, 2016 | 99.63M |
| March 31, 2016 | 99.32M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 2.296M |
| June 30, 2014 | 1.589M |
| March 31, 2014 | 39.65M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | 178.13M |
| ACADIA Pharmaceuticals, Inc. | 59.55M |
| Alnylam Pharmaceuticals, Inc. | 2.942B |
| Anika Therapeutics, Inc. | 23.32M |
| Savara, Inc. | 30.11M |